eGenesis押注基因编辑猪肾，解决器官短缺问题

做的是什么生意

A clinical-stage biotechnology company doing xenotransplantation: it uses genetically edited pigs to produce organs such as kidneys for human transplantation, first advancing pipeline product EGEN-2784 pig kidney into FDA clinical trials.

启动资金：Early disclosed funding of $38M (2017, Harvard Gazette); completed a $191M Series D round in 2024-09 (led by Lux Capital).

起因

Founded in 2015 by Harvard Medical School geneticist George Church and former doctoral student Luhan Yang, spun out from Church's lab and licensed Harvard technology. Starting judgment: the biggest obstacles to xenotransplantation are immune rejection and porcine endogenous retroviruses (PERV), and this is exactly the multigene editing problem that CRISPR is good at—in 2015 the lab showed in Science the elimination of all 62 PERVs in pig cells, and in 2017 it also worked with eGenesis to produce 37 PERV-free pigs.

经过

In 2024-03, under FDA Expanded Access authorization, Massachusetts General Hospital completed the world's first genetically edited pig kidney transplant in a living patient; in 2024-09, it completed a $191M Series D round (led by Lux Capital) to advance EGEN-2784 into formal clinical research; on 2025-01-25, Tim Andrews received a transplant at MGH and was dialysis-free for more than 7 months after surgery, becoming the longest-surviving recipient of a genetically edited pig-derived organ; on 2025-06-14, Bill Stewart became the 2nd recipient in the study and the 3rd recipient globally; on 2025-09-08, FDA approved the IND for EGEN-2784, supporting a Phase 1/2/3 trial in patients aged ≥50, dialysis-dependent, and on transplant waiting lists with end-stage kidney disease (assessed 24 weeks after transplant).

可借鉴之处

将愿景转化为可审计的里程碑；每一步都有公开记录，因此投资者在试验前就愿意出资。